Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Training of Clinical Staff on Protocol Amendments – V 2.0

Posted on By

BA-BE Studies: SOP for Training of Clinical Staff on Protocol Amendments – V 2.0

Standard Operating Procedure for Training of Clinical Staff on Protocol Amendments in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/101/2025
Supersedes SOP/BA-BE/101/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define the procedure for training all relevant clinical staff on protocol amendments to ensure proper implementation and regulatory compliance in BA/BE studies.

2. Scope

This SOP applies to investigators, sub-investigators, study nurses, pharmacists, CRCs, and other staff directly or indirectly involved in the execution of amended protocols at clinical research units conducting BA/BE studies.

3. Responsibilities

  • Principal Investigator (PI): Ensures understanding and implementation of amended protocol.
  • Quality Assurance (QA): Verifies that training has been conducted and documented.
  • Training Coordinator: Organizes, schedules, and maintains training records for all protocol amendments.
  • Clinical Research Coordinator (CRC): Ensures attendance and acknowledgment of training by staff involved in respective procedures.
See also  BA-BE Studies: SOP for IMP Accountability Logs - V 2.0

4. Accountability

The PI and QA Head are jointly accountable for ensuring that protocol amendments are trained prior to implementation and that deviations from the amended protocol do not occur due to lack of awareness.

5. Procedure

5.1 Receipt of Protocol Amendment

  1. Once a protocol amendment is approved by the Ethics Committee and sponsor, the copy shall be received and filed in the site master file (SMF).
  2. Assign the amendment a version number and date for traceability.

5.2 Training Plan Development

  1. Training Coordinator creates a training plan that includes:
    • Summary of changes in the amendment
    • List of impacted study procedures
    • List of staff requiring training
    • Timeline for training completion
  2. Document plan using Annexure-1: Protocol Amendment Training Plan Template.

5.3 Conduct of Training

  1. Training may be conducted via:
    • Group sessions
    • One-on-one discussions (for specific roles)
    • Recorded webinars with assessment
  2. Trainer to use Annexure-2: Protocol Amendment Summary Slides and maintain attendance sheet (Annexure-3).
See also  BA-BE Studies: SOP for Study Timelines and Milestone Management - V 2.0

5.4 Assessment and Documentation

  1. Post-training, each staff must:
    • Sign the acknowledgment log (Annexure-4)
    • Pass assessment if applicable (Annexure-5)
  2. Training records must be archived in the Training File section of the TMF.

5.5 Implementation and Follow-Up

  1. No procedures under the amended protocol are to begin until training is completed.
  2. QA to verify training completion before the first implementation activity and record in Annexure-6: QA Compliance Checklist.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • PI: Principal Investigator
  • CRC: Clinical Research Coordinator
  • QA: Quality Assurance
  • TMF: Trial Master File

7. Documents

  1. Protocol Amendment Training Plan – Annexure-1
  2. Training Slide Summary – Annexure-2
  3. Attendance Sheet – Annexure-3
  4. Acknowledgment Log – Annexure-4
  5. Training Assessment Sheet – Annexure-5
  6. QA Compliance Checklist – Annexure-6

8. References

  • ICH E6(R2) – Good Clinical Practice
  • Indian GCP Guidelines
  • Schedule Y – Drugs and Cosmetics Rules

See also  BA-BE Studies: SOP for Integrating BA/BE Studies in Global Clinical Strategy - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Protocol Amendment Training Plan

Amendment Version Date Key Changes Impacted Staff Deadline
V2.1 15/04/2025 Change in PK sampling times Nurses, CRCs 18/04/2025

Annexure-2: Summary Slide Sample

Slide Title Slide Description
PK Sample Changes Sampling window reduced from ±5 to ±3 min

Annexure-3: Attendance Sheet

Name Designation Signature Date
Rajesh Kumar Study Nurse Signed 17/04/2025

Annexure-4: Acknowledgment Log

Name Protocol Amendment No. Understanding Confirmed Signature
Sunita Reddy Amendment V2.1 Yes Signed

Annexure-5: Training Assessment Sheet

Name Score Result Trainer Signature
Ajay Verma 90% Pass Trainer

Annexure-6: QA Compliance Checklist

Item Verified Comments QA Signature
Attendance Logs Yes Complete QA Officer

Revision History:

Revision Date Revision No. Details Reason Approved By
10/01/2022 1.0 Initial release New process QA Head
17/04/2025 2.0 Annexures and process flow added GCP alignment QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: API Manufacturing: SOP for In-Process Sampling Technique – V 2.0
Next Post: Creams: SOP for Conducting Spreadability Tests on Creams – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version